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IMPLEMENTATION OF HIGH DOSE INTERVAL VITAMIN D 
SUPPLEMENTATION IN PEDIATRIC PATIENTS WITH INFLAMMATORY 
BOWEL DISEASE RECEIVING REMICADE 
 
CAMILLE E. T. JOHANSEN 
 
ABSTRACT 
BACKGROUND: Patients who have been diagnosed with Inflammatory Bowel Disease 
(IBD) present with increased risk of deficient vitamin D levels. Previous studies have 
demonstrated that these IBD patients who live in areas with lack of sun exposure are 
especially susceptible to becoming vitamin D deficient. Studies have also shown that the 
standard vitamin D dosing protocols have not proven effective in consistently improving 
vitamin D status. This failure is likely related to a combination of under-dosing and 
patient noncompliance. Vitamin D sufficiency is essential in the maintenance of both 
skeletal health and the immune system in children and adolescents. 
OBJECTIVES: The primary aim of this study is to investigate the safety and efficacy of 
administering an interval, high dose oral vitamin D supplementation in pediatric patients 
with IBD treated with Remicade. A secondary aim is to study the association between 
changes in serum 25OHD (25-hydroxyvitamin D3) levels and clinical and biochemical 
markers of IBD. The findings from this study will provide preliminary data for future 
studies using serial measurements of serum 25OHD levels to better articulate the optimal 
dosage for interval vitamin D supplementation in pediatric patients with IBD. 
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METHODS: We identified and screened pediatric patients with IBD at Boston Children’s 
Hospital (BCH) with vitamin D deficiency (serum 25OHD level < 30 ng/mL). Vitamin D 
dosing was determined by a patient’s Remicade interval. Patients received either 50,000 
international units (IU) of vitamin D3 (every 4-5 weeks) or 100,000 IU of vitamin D3 
(every 6-8 weeks), concurrent with their Remicade infusion interval. Longitudinal data, 
including anthropomorphic measurements, serum chemistry labs, spot urine calcium to 
creatinine ratios, quality of life metrics, and surveys gauging dietary vitamin D intake and 
sunlight exposure, were collected throughout the study. 
RESULTS: Baseline vitamin D status in the 60 enrolled patients did not differ by gender, 
dosing group, diet, or diagnosis (Crohn disease, ulcerative colitis, or indeterminate 
colitis). Of the 57 patients for whom baseline and final serum 25OHD levels were 
available, there was a significant increase in total serum 25OHD levels from 22.53 ± 4.65 
ng/mL to 29.91 ± 6.60 ng/mL, respectively. Similarly, increases in mean serum 25OHD 
levels were noted in both dosing formats and disease groups. Interestingly, there was no 
significant parallel impact of increased 25OHD levels on either disease activity or quality 
of life. There were no significant changes in serum calcium, phosphorous, and creatinine 
levels in response to changes in 25OHD levels. There were no reports of significant 
adverse events related to vitamin D supplementation. 
CONCLUSION: High dose, interval vitamin D supplementation improved vitamin D 
status from baseline in a majority of studied pediatric patients with IBD. The data suggest 
that this type of interval, high dose format is likely more effective than more traditionally 
once-daily dosing. Further studies are necessary to determine the optimal dosage 
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Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a term used to describe a collection of 
disorders causing chronic inflammation in the digestive tract. The two main types of IBD 
are Crohn Disease (CD) and ulcerative colitis (UC). The inflammation observed in 
patients with CD can occur in any region of the gastrointestinal (GI) tract spanning from 
the mouth to the anus. In contrast, the inflammation observed in patients with UC is 
limited to the lining of the large intestine. Patients diagnosed with CD and UC can 
present with similar symptoms, including bloating, abdominal pain, and diarrhea (Perler 
et al., 2019). Patients with IBD can also experience non-gastrointestinal symptoms, 
including fatigue, urinary urgency, and a range of psychological problems (Whorwell, 
McCallum, Creed, & Roberts, 1986). Together, these symptoms lead to a decreased 
quality of life for these patients. While there is no cure for IBD, current treatment plans 
target managing clinical symptoms, reducing chronic mucosal inflammation, and 
preventing the development of any complications of the disease, including perforation or 
stricture formation (Wylezinski, Gray, Polk, Harmata, & Spurlock, 2019). 
The prevalence of individuals in the United States diagnosed with IBD has 
steadily increased over the course of the last decade, and current numbers stand at 
approximately 250 per 100,000 for adults and approximately 45 per 100,000 individuals 
under 20 years of age (Kappelman, Moore, Allen, & Cook, 2013a). Around 25-30% of 
patients with CD, and about 20% with UC, are diagnosed before the age of 20 (Kelsen & 
Baldassano, 2008). Trends in recent epidemiological studies have revealed a higher 
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prevalence of pediatric patients with IBD in the Northeast and Midwest regions compared 
to that observed in the Southern and Western regions of the United States (Tables 1 and 
2). This observation is consistent with a current hypothesis implicating that decreased sun 
exposure during the winter season at higher latitudes, such as the Northeast and Midwest, 
may negatively impact IBD-related symptoms (Holmes, Harris, & Lucas, 2019). Lack of 
sun exposure is also a significant factor that contributes to vitamin D deficiency (Holmes 
et al., 2019). Current studies have demonstrated that children with IBD are more likely to 
be vitamin D deficient (25OHD < 20 ng/mL), and on average, had lower serum 25OHD 
concentrations relative to controls (Nwosu, Maranda, & Candela, 2017). This finding 
may be especially relevant for children with IBD who are more at risk for malabsorption 
and inadequate nutrition and, therefore, more likely to experience detrimental effects on 
their linear growth and pubertal development (Kelsen et al., 2008). As such, new efforts 
have focused on the assessment and optimization of vitamin D levels in children and 
adolescents with IBD. 
Table 1. Prevalence of Pediatric Crohn Disease in the U.S. Incidence of CD per 
100,000 pediatric patients. Recorded by U.S. region from 2008 to 2009; adapted from 






Table 2. Prevalence of Pediatric Ulcerative Colitis in the U.S. Incidence of UC per 
100,000 pediatric patients. Recorded by U.S. region from 2008 to 2009; adapted from 
(Kappelman et al., 2013b). 
 
 
Vitamin D Deficiency 
Vitamin D plays a significant role in maintaining calcium homeostasis and 
immune function. Sources of vitamin D3 (cholecalciferol) include dietary intake or 
dermal synthesis in response to exposure to ultraviolet irradiation (Christakos, Ajibade, 
Dhawan, Fechner, & Mady, 2010). The primary functional determinant of vitamin D 
status in patients can be assessed in the level of the active form of vitamin D3, or 1,25-
dihydroxyvitamin D3 (1,25(OH)2D). After vitamin D3 is 25-hydroxylated in the liver, this 
moiety is further hydroxylated at the 1-position by vitamin D3-1α-hydroxylase 
(CYP27B1) in the kidney to form 1,25(OH)2D (Figure 1). This active form of vitamin D3 
binds to and activates the vitamin D receptor (VDR) in target tissues, including cells 
involved in immune regulatory pathways (Yin & Agrawal, 2014). Activation of the VDR 
by 1,25(OH)2D suppresses immune responses mediated by T cells and dendritic cells in 





Figure 1. Pathway for Vitamin D3 Metabolism. Synthesis of 1,25(OH)2D in the kidney 
from vitamin D3. The active form of vitamin D3 proceeds to bind various target tissues, 
including immune cells; adapted from (Christakos et al., 2010). 
Data from in-vitro studies support an interaction of 1,25(OH)2D with the VDR in 
the intestinal mucosa, and this has implications for the subsequent development of colitis. 
Active VDR signaling reduces cytokine-induced apoptosis of intestinal epithelial cells 
(IEC) and thus serves a protective role for the gut mucosal barrier. This mechanism is 
supported by data from animal studies demonstrating that VDR-deficient null mice do not 
develop colitis and avoid IEC death when injected with the human vitamin D receptor 
(hVDR) transgene (Liu et al., 2013). In another animal study, researchers used 2,4,6-
trinitrobenzene sulfonic acid (TNBS) to induce a chronic colitis that mirrors Crohn 
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Disease in two lines of transgenic mice to further assess the effects of epithelial VDR 
deletion on excessive mucosal inflammation (He et al., 2017). The data from these 
studies demonstrated that VDR deletion increased musical inflammation through 
overactivation of the p53-upregulated modulator of apoptosis (PUMA)-mediated 
proapoptotic pathway. This resulted in the development of significant defects in the 
epithelial barrier dysfunction, and an increased likelihood of bacteria and luminal 
antigens gaining access to the epithelial submucosa and resident immunocompetent cells. 
These data, therefore, further support the protective role played by the VDR in immune 
functioning. 
While data from several murine studies suggest a relationship between vitamin D 
levels and activity and colitis, there are only a few studies in humans that support an 
inverse relationship between VDR activity and intestinal inflammatory markers. In a 
more recent study, Garg and colleagues collected colonoscopic biopsies and intestinal 
resection specimens from patients with IBD. The study demonstrated an inverse 
relationship between fecal calprotectin levels, a marker of intestinal inflammation, and 
VDR transcript expression (Garg et al., 2019). Data from epidemiological studies further 
point toward a negative association between circulating vitamin D3 levels and colonic 
inflammatory status. A retrospective study conducted at Brigham and Women’s Hospital 
demonstrated a significant association between higher serum 25OHD levels (>33 ng/mL) 
and an increased likelihood of remission with initial exposure to anti-tumor necrosis 
factor-a (TNFa) therapy among patients with IBD (Winter et al., 2017). The researchers 
cited that patients who were vitamin D3 deficient (25OHD levels <33 ng/mL) had a 
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decreased likelihood of responding to anti-TNF medication within the first three months 
of its initiation. In a case-control study, Wu and colleagues evaluated the relationship 
between vitamin D3 status and colon and colorectal cancers. The study found that there 
was a statistically significant inverse association between colon cancers and higher (>40 
ng/mL) 25OHD levels (Wu et al., 2007). These data suggest that an increased incidence 
of colon cancer may be a long-term effect of chronic vitamin D3 deficiency in patients 
with IBD (Olén et al., 2017). 
There is growing recognition of the association between low vitamin D levels and 
low bone mineral density, specifically in patients with inflammatory bowel disease. In 
2011, IBD clinical guidelines were published that included a formal recommendation to 
monitor vitamin D status in efforts to both boost immune function as well as to optimize 
bone health (Mowat et al., 2011). In the years following, several studies identified a low 
vitamin D level as an independent risk factor, along with inflammation, reduced physical 
activity, and prolonged steroid usage, for low bone mineral density and increased fracture 
risks in children with IBD (Pepe et al., 2017; Wong, Catto-Smith, & Zacharin, 2014). 
However, additional studies are necessary to assess further the complicated 
relationship(s) between vitamin D intake, serum levels, and bone mineral density in 
pediatric patients with IBD. 
 
Vitamin D Supplementation and Dosage 
Vitamin D participates in several physiologic pathways, and its level and activity 
are tightly regulated. Factors contributing to vitamin D deficiency in both the general 
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population, as well as in patients with IBD, include seasonal variation, dietary sources, 
and parathyroid (PTH) activity (Kojecky, Adamikova, & Klimek, 2016). Current 
guidelines for the recommended daily allowance (RDA) of vitamin D in adults range 
from 600-800 IU per day, and prescribed daily vitamin D supplements typically range 
from 1,000-2,000 IU per day (Kojecky et al., 2016). Recommendations from the Federal 
Drug Administration (FDA) and Institute of Medicine (IOM) recommend that overall 
vitamin D intake should not exceed 4,000 IU per day (Ross et al., 2011). 
Vitamin D3 has a greater affinity for its carrier protein, vitamin D-binding protein 
(DBP), relative to vitamin D2. Furthermore, there is evidence demonstrating that vitamin 
D3 is the better clinical metric for circulating serum 25OHD activity, compared to 
vitamin D2 (Armas, Hollis, & Heaney, 2004; Yin et al., 2014). Pharmacokinetic studies 
demonstrated that a single oral dose of 100,000 IU of vitamin D3 will reach a peak (42 
ng/mL) 25OHD level about one week after administration, and the level will gradually 
return to pretreatment levels over the next 12 weeks (Ilahi, Armas, & Heaney, 2008). No 
subjects experienced hypercalcemia or increased levels of PTH. Furthermore, 7% of the 
cohort failed to achieve a serum 25OHD level at or above 32.0 ng/mL at any time point 
after this single high dose vitamin D supplementation protocol. A distinguishing feature 
of this particular cohort was that their baseline levels were between 15-18 ng/mL, which 
is considerably below the recommended levels of serum 25OHD. 
There are no current standards for recommended vitamin D intake specific to 
children or adults with IBD. Data from existing studies has demonstrated the safety and 
efficacy of oral vitamin D3 supplementation in pediatric patients with IBD patients, with 
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only rare cases of transient hypercalcemia and hyperphosphatemia (Pappa et al., 2014). In 
the same prospective and randomized study, it was shown that a dose of 2,000 IU of 
vitamin D3 supplements was not adequate to normalize the serum 25OHD levels in 
children with IBD (Pappa et al., 2014). Since about 35% of children with IBD are 
considered vitamin D deficient, these studies suggest that the determination of a 
standardized vitamin D regimen could provide a means to more decisively address 
hypovitaminosis D (Pappa et al., 2014). Currently, few studies have demonstrated a 
dosage regimen to treat IBD pediatric patients that is both effective and feasible in terms 
of compliance. Studies have suggested that body weight should be considered a factor in 
determining a particular dosage for pediatric patients with IBD (Pappa et al., 2014). 
Therefore, there is a need for larger and more definitive research to determine an 
effective vitamin D supplementation regimen for pediatric patients diagnosed with IBD. 
 
Remicade (Infliximab) Infusion 
Inflammatory bowel disease is a chronic inflammatory GI disease for which there 
is currently no cure. Current treatment regimens target clinical and mucosal remission 
through the oral or parenteral administration of immunosuppressive or anti-inflammatory 
therapies. Infliximab (brand name Remicade) is a parenterally administered chimeric 
monoclonal antibody that acts as an anti-TNFa medication (Papamichael et al., 2019). 
Remicade holds FDA indication for the treatment of both forms of IBD, including CD 
and UC, in adult and pediatric patients, aged six years and older, who have failed to 
respond to other therapies (Janssen Biotech, Inc., 2017). Infliximab is typically 
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administered every 4-8 weeks (Hyams et al., 2007). Interestingly, there is preliminary 
data correlating higher levels of 25OHD in patients with IBD receiving TNFa inhibitors 
(Schäffler et al., 2018). 
 
Objectives 
This study aims to investigate the safety and efficacy of two regimens of interval, 
high dose oral vitamin D supplementation in the treatment of vitamin D deficiency in 
pediatric patients with IBD receiving Remicade. A secondary aim is to study the 
association between changes in serum 25OHD levels and clinical and biochemical 
markers of IBD. The findings from this study would provide preliminary data for further 
studies directed at determining the optimal interval dosing regimen for vitamin D 






The eligible population for this prospective research study includes patients 
between the ages of 0-25 years old who had an existing diagnosis of inflammatory bowel 
disease, including ulcerative colitis, Crohn Disease, and indeterminate colitis (IC). All 
patients were being treated at Boston Children’s Hospital and were receiving scheduled 
Remicade infusions as prescribed by their GI physicians. Study subjects were identified 
via a chart review through the electronic medical record (EMR) at BCH. The eligible 
study population was further limited to those with a previously measured serum level of 
25OHD that was below 29 ng/mL no later than October 1, 2016. These patients were 
considered vitamin D insufficient and were eligible to enroll in the study within eight 
weeks of their most recent vitamin D level. However, patients who had changed their 
vitamin D supplementation during this 8-week interim were considered ineligible for the 
study. Furthermore, patients with a serum level of 25-OH vitamin D ≥ 30.00 ng/mL were 
considered vitamin D sufficient and ineligible for participation in the study. 
Additional exclusion criteria included patients with a history of underlying kidney 
disease, pre-existing liver disease, or granulomatous disease, due to concerns for their 
ability to safely metabolize vitamin D. Patients with a history of hypercalcemia or 
hypercalciuria were further excluded from the study due to health concerns over the 
possibility of hypervitaminosis D. Patients were also considered ineligible from the study 





After a thorough review of the medical chart for each subject, we identified a 
cohort of patients who were eligible for the study. Enrollment goals included 25 patients 
with UC and 25 patients with CD. The primary GI physicians of these patients were 
notified to assess their suitability for participation in the study. After receiving verbal or 
written approval from each patient’s GI physician, eligible subjects were approached for 
consent during a scheduled Remicade infusion or ambulatory GI follow-up appointment. 
The risks and benefits of the study were explained to potential subjects and their 
parents/guardians. They were encouraged to ask any questions about the study. Following 
this discussion, subjects and their parents were asked to provide assent and consent, 
respectively, and they were enrolled in the study. 
 
Vitamin D Dosage 
Upon enrollment, patients were assigned to one of the two vitamin D dosage 
groups. Patients receiving their Remicade infusions every four to five weeks were 
provided with 50,000 IU of vitamin D3 during their infusion. In contrast, patients 
receiving their Remicade infusions every six to eight weeks were provided with 100,000 
IU of vitamin D3 during each of their Remicade infusions. Patients were given one 
50,000 vitamin D capsule if they were in the 50,000 IU dose group, or two vitamin D 
capsules if they were in the 100,000 IU dose group, at their next scheduled Remicade 
infusion. This infusion appointment was labeled “Infusion 1.” The patients received the 
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assigned vitamin D supplementation at each subsequent Remicade infusion for 
approximately one year. 
The supplements administered to the patients during the study were D3-50 50,000 
IU vitamin D3 capsules manufactured by Bio-Tech Pharmacal, Inc. in Fayetteville, AR. 
The other ingredients in the supplements included microcrystalline cellulose and gelatin. 
 
Surveys and Laboratory Data 
After consent, research subjects completed the IMPACT-III survey, a 35-item 
health-related quality of life (HRQoL) metric for use in pediatric patients with IBD 
(Griffiths et al., 1999; Abdovic et al., 2013). Coincident with the administration of their 
first high dose vitamin D supplement administration, patients completed a baseline 
survey (Appendix A) which included questions regarding their medical history, race and 
ethnicity, skin sensitivity and pigmentation, and sources of dietary vitamin D. The 
purpose of this survey was to estimate the individual patient’s average exposure to 
sunlight and dietary vitamin D intake. Further baseline measures were extracted using the 
BCH EMR to determine baseline Remicade laboratory work, prior hospitalizations and 
surgeries, previous orthopedic issues, radiology scans, and concurrent medications. The 
most recent clinical assessment of disease activity was identified in the EMR through the 
Abbreviated Pediatric Crohn Disease Activity Index (aPCDAI; Table 3) or Pediatric 
Ulcerative Colitis Index (PUCAI; Table 4). At subsequent infusions, patients completed a 
follow-up survey (Appendix B) to routinely reassess their dietary vitamin D intake and 
exposure to sunlight. Patients were also given an activity questionnaire to evaluate their 
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physical activity level and to document any recent hospital admissions. At each infusion, 
data including anthropomorphic measures, changes in Remicade dosing, concurrent 
medications, diagnostic studies, and hematology and blood chemistry labs were also 
collected (Table 5). 
Table 3. Abbreviated PCDAI. Scores range from 0-70. Cutoff scores include remission 
(<10 points), mild (10-25), moderate (26-39), and severe disease (>40); adapted from 





Table 4. PUCAI. Scores range from 0-85. Cutoff scores include remission (<10 points), 
mild (10-34), moderate (35-64), and severe disease (>65); adapted from (Bousvaros et 
al., 2009). 
 
At every even-numbered infusion, such as “Infusion 2, 4, 6, etc.,” serum 25OHD, 
spot urine calcium, spot urine creatinine, and spot urine calcium to creatinine ratio 
(Ca/Cr) levels were measured. The serum 25OHD level was collected to evaluate for 
efficacy and the Ca/Cr was calculated to monitor for hypercalciuria. If a patient’s Ca/Cr 
was >0.200, he or she would receive a follow-up spot urine Ca/Cr ordered to be done at 
their next scheduled Remicade infusion (4 to 8 weeks later). If a patient was determined 
to have two subsequent spot Ca/Cr ratios >0.200, a 24-hour urine collection would be 
ordered to verify evidence of hypercalciuria and possible evaluation of their continued 
participation in the study. 
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Patients in the 100,000 IU dose group completed an IMPACT-III (HRQoL) 
survey along with follow-up diet and activity questionnaires when they received their last 
vitamin D dose at Infusion 8. Their disease activity was also extrapolated from the BCH 
EMR using the most recent aPCDAI or PUCAI score at their last infusion. Patients in the 
50,000 IU dose group completed IMPACT-III, follow-up, and activity surveys at Infusion 
8 and then Infusion 12, which is their last dose of vitamin D3. Their disease activity 
scores were also recorded from the BCH EMR at Infusion 8 and 12. (Table 5). 
Item Date of 
Consent 












Consent Form X             
IMPACT-III 
(HRQoL) 
X        X    X 
aPCDAI/ 
PUCAI 
 X       X    X 
Baseline 
Survey 
 X            
Clinical Care 
Labs 
 X X X X X X X X X X X X 
Follow-Up 
Survey 
  X X X X X X X X X X X 
Activity 
Questionnaire 
  X X X X X X X X X X X 
High Dose 
Vitamin D3 
 X X X X X X X X X X X X 
Serum 
25OHD 
  X  X  X  X  X  X 
Spot Urine 
Ca/Cr Sample 
  X  X  X  X  X  X 
Table 5. Data collection schedule. Subjects were monitored for 48-64 weeks, depending 
on the duration between his or her Remicade intervals. Subjects receiving the 100,000 IU 
dose completed the study at Infusion 8 while those receiving the 50,000 IU were 
evaluated until Infusion 12. When deemed appropriate, date of consent was concurrent 
with Infusion 1. 
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Data Collection and Analysis 
All clinical, laboratory, and survey data collected from the patients were 
transferred into Case Report Forms on Research Electronic Data Capture (REDCap). This 
program is a Health Insurance Portability and Accountability Act of 1996 (HIPAA)-
compliant web application that is supported by BCH. Data exported from REDCap were 








A total of 512 pediatric patients diagnosed with IBD receiving Remicade were 
screened for serum 25OHD status between October of 2017 and November of 2018. Of 
these, 386 (75.4%) had serum 25OHD levels measured between October 1, 2016, and 
November 30, 2018. There were 126 patients who had no previously recorded 25OHD 
level. From this available sample of 386 patients, 188 (48.7%) had serum 25OHD levels 
> 30 ng/mL and were considered vitamin D sufficient. Of the 198 (51.3%) patients with 
25OHD levels < 30 ng/mL, 48 (24.2%) were ineligible due to the absence of a 25OHD 
level that fell within the requisite eight weeks from the date of consent. After screening 
for pre-existing liver disease/dysfunction, kidney disease, granulomatous disorders, and 
dysphagia conditions, an additional 14 patients were excluded, and the remaining 136 
patients were eligible to approach. 77 (56.7%) of these patients would be available for the 
expected duration of the study and were deemed appropriate for the research by their 
primary GI providers. Upon approach, 8 patients declined, and the remaining 69 patients 
(89.6%) consented. However, 3 patients were unable to swallow the study capsules, and 1 
was determined to be allergic to gelatin, an inactive ingredient in the vitamin D3 capsule 
formulation. These 4 patients were disenrolled, and a total of 65 remained active 
participants in the study. Of these patients, 5 were ultimately excluded for noncompliance 
with either their scheduled Remicade infusions or with taking study capsules, 2 withdrew 
to return to prescribed supplementation as ordered by their providers, 1 voluntarily 
withdrew from the study as a result of nausea that they experienced while taking the 
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vitamin D3 dose, 4 patients transferred to adult care or another hospital, 2 patients 
discontinued Remicade and switched to a different maintenance medication, and 1 patient 
was lost to follow-up. This left a final enrollment of 50 patients (Figure 2). 
 
Figure 2. Subject Screening and Recruitment. A total of 512 pediatric patients 
receiving scheduled Remicade infusions for IBD at BCH were screened for vitamin D 
status and study eligibility between October of 2017 and November of 2018. A total of 65 
patients were enrolled, and 15 were excluded post-enrollment based on the protocol 




65 patients were initially enrolled. However, 5 patients were removed from the 
study before completing the baseline surveys or receiving a second dose, and 10 were 
either retroactively removed or lost to follow up after receiving 3 or more infusions. 
Therefore, baseline and follow-up data were available from a total of 60 subjects from 
both dosing groups. 
68.0% of enrolled subjects were male (41) and 32.0% female (19). The 
distribution was similar across dosing groups as males comprised 66.7% (12) of subjects 
in the 50,000 IU dose group and 69.0% (29) of subjects in the 100,000 IU groups. The 
mean age at the time of consent was 16.50 ± 3.83 years, and the 100,000 IU cohort were 
slightly older, on average, than those in the 50,000 IU dose group. The mean Body Mass 
Index (BMI) at the time of consent was 23.90 ± 5.70 kg/m2, with subjects in the 50,000 
IU dose group recording a slightly higher BMI, on average, than those in the 100,000 IU 
dosing group. 70.0% of patients identified themselves as being White (42), 21.6% as 
Other (13), 6.7% as Black/African American (4), 1.7% as Asian (1), and 0.0% as Native 
American/Alaskan Native (0). The distribution was similarly reflected across the two 
vitamin D dose groups (Table 6). 
All patients in the study carried a diagnosis of IBD. 75.0% of patients had CD 
(45), 23.2% had UC (14), and 1.7% had IC (1). The distribution of disease diagnoses was 
similar across the two dosing groups. All subjects enrolled in the study had a baseline 
serum 25OHD level that was considered vitamin D deficient (<30 ng/mL). At the time of 
consent, the mean serum 25OHD level was 22.45 ± 4.67 ng/mL for all participating 
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subjects, 21.17 ± 5.70 ng/mL in the 50,000 IU dose group, and 23.00 ± 4.07 ng/mL in the 
100,000 IU dose group. All study patients completed regularly scheduled Remicade 
infusions as their maintenance medication for IBD. 43.3% (26) subjects relied only on 
Remicade as their maintenance medication, while the remaining 57.7% (34) of subjects 
received concomitant immunomodulator, aminosalicylate, or steroid therapy (Table 6). 
Table 6. Demographics and Clinical Characteristics. Description of the 60 patients 
who enrolled in the study, completed baseline data, and were assigned to a vitamin D 
dose group, based on their schedule of Remicade infusions. 
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Vitamin D Levels 
All patients enrolled were screened and identified as vitamin D deficient, with a 
total serum 25OHD level of less than 30.00 ng/mL within 8 weeks of consent. The 
average pretreatment serum 25OHD level for male subjects (21.73 ± 4.91 ng/mL) was 
not significantly different from that observed in female subjects (24.00 ± 3.73 ng/mL), as 
assessed using an unequal variance t-test (t, -1.97; confidence interval [CI], -4.58 – 0.05; 
p = 0.06). Similarly, unequal variances t-tests did not demonstrate a difference in mean 
baseline vitamin D status between patients with CD (22.22 ± 4.74 ng/mL) and those with 
UC (23.02 ± 4.68 ng/mL; t, -0.06; CI, -3.78 – 2.17; p = 0.58). The extent of vitamin D 
deficiency did not correlate with age (p = 0.34), BMI (p = 0.46), or dietary intake of 
vitamin D (p = 0.64). However, increased sun exposure reported as daily typical clothing 
coverage and ranging from just head and neck to “bathing suit” exposure was positively 
correlated with baseline 25OHD levels (p < 0.001). There was no observed difference in 
baseline serum 25OHD levels based on the month of the year in which treatment was 
initiated (p = 0.24). 
The dose of vitamin D3 administered to subjects was based on the interval 
between their scheduled Remicade infusion intervals. On average, subjects in both dose 
groups reached steady-state serum 25OHD levels after administration of three doses, 
which was about four to eight months after the initial treatment. Steady-state serum 
25OHD levels were 28.91 ± 5.60 ng/mL and 33.18 ± 5.80 ng/mL for the 50,000 IU and 
100,000 IU dosing groups, respectively. In general, these levels increased from baseline 
levels for both the 50,000 IU (21.17 ± 5.70 ng/mL) and 100,000 IU (23.00 ± 4.07 ng/mL) 
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dose groups (p < 0.01) as assessed by paired t-test analysis. The increase in 25OHD 
levels from baseline was 7.74 ng/mL in the 50,000 IU dose group and 10.18 ng/mL in the 
100,000 IU dose group, but these increases were not statistically different (p = 0.11). The 
change in vitamin D status was similar in patients with CD and UC (p = 0.19), as well as 
between genders (p = 0.12). 
Baseline and final serum 25OHD levels were available from a total of 60 subjects 
in the study. However, 3 subjects were excluded from the final serum 25OHD level 
analysis when it was discovered that these subjects had received additional vitamin D3 
supplementation before receiving their last study dose, which occurred at either Infusion 
8 or Infusion 12. Therefore, paired baseline and final serum 25OHD levels were available 
from 57 subjects in the study. These patients had an average baseline serum 25OHD level 
of 22.53 ± 4.65 ng/mL and an average final serum 25OHD level of 29.91 ± 6.60 ng/mL 
(Figure 3). These serum 25OHD levels were statistically increased (p < 0.0001) from 
baseline to final infusion in the total study population (t, 8.00; CI, -9.22 - -5.53). At 
baseline, the minimum 25OHD level was 10.60 ng/mL, the maximum was 29.80 ng/mL, 
and the median was 23.10 ng/mL across the study population. At the time of their final 
vitamin D administration, the minimum serum 25OHD level was 15.60 ng/mL, the 





Figure 3: Effect of high dose therapy on total serum 25OHD. 57 of the 60 enrolled 
patients treated with high dose therapy reported baseline and final vitamin D3 status. A 
significant increase in overall 25OHD levels occurred from baseline to final infusion in 
this total study population (p < 0.001). 
 
A significant increase in 25OHD levels was noted in both dosing groups in the 
interval between their baseline and final infusions. A significant increase in serum 
25OHD levels was noted in the 16 subjects in the 50,000 IU dosing group with a baseline 
serum level of 20.28 ± 6.29 ng/mL and a final level of 28.54 ± 7.32 ng/mL (t, 3.45; CI, -
13.15 - -3.37; p = 0.002). In the 100,00 IU dosing group of 41 subjects, there was also a 
statistically significant increase in serum 25OHD levels with a baseline 25OHD level of 
23.42 ± 3.55 ng/mL and a final 25OHD level of 30.44 ± 6.35 ng/mL, (t, 7.23; CI, -8.99 - -
5.06; p < 0.0001) (Figure 4). Of these 57 patients, 42 patients were diagnosed with CD 






























25OHD levels of 29.68 ± 6.35 ng/mL at their last infusion, (t, 7.32; CI, -9.40 - -5.33; p < 
0.0001). These data further illustrate a statistically significant increase in serum 25OHD 
levels from baseline to the end of the study among the CD cohort. A significant increase 
in vitamin D levels was similarly noted in the 14 patients with UC who had baseline 
serum 25OHD levels of 23.02 ± 4.68 ng/mL and final serum 25OHD levels of 29.99 ± 
7.40 ng/mL, (t, 3.10; CI, -11.84 - -2.11; p = 0.009) (Figure 5). Of note, the one patient 
diagnosed with IC had a baseline and final serum 25OHD level of 25.00 ng/mL and 
38.30 ng/mL, respectively. Overall, mean serum 25OHD levels demonstrated statistically 
significant increases from baseline to final infusion across the total study population, as 










Figure 4: Effect of high dose therapy on total serum 25OHD across dose groups. Of 
the 57 patients, 16 were assigned to the 50,000 IU dose group (top) and 41 were assigned 
to the 100,000 IU dose group (bottom) based on their scheduled Remicade infusion. A 
significant increase in total 25OHD levels occurred from baseline to final infusion in both 































































Figure 5: Effect of high dose therapy on total serum 25OHD across disease state. Of 
the 57 pediatric patients, 42 were diagnosed with CD (top) and 14 were diagnosed with 
UC (bottom). A significant increase in total 25OHD levels occurred from baseline to final 




























































Blood chemistry labs were monitored to assess for side effects that could be 
related to high circulating vitamin D levels, including hypercalcemia and kidney stones. 
Safety laboratory data assessed at baseline and study closure did not remarkably change 
throughout the study. Serum calcium levels in the 50,000 IU dose group were 9.26 ± 0.45 
mg/dL at baseline and 9.43 ± 0.42 mg/dL at the time of the patients’ final infusion. 
Creatinine levels in this dose group were 0.63 ± 0.24 mg/dL at baseline and 0.60 ± 0.21 
mg/dL at the time of the last infusion. At baseline, phosphorous levels were 3.82 ± 0.64 
mg/dL, and they rose to 4.06 ± 0.68 mg/dL at study closure. Similarly, mean blood 
chemistry laboratory levels did not statistically increase in the 100,000 IU dose group. 
Calcium levels in this dosage group were 9.34 ± 0.33 mg/dL at baseline and 9.48 ± 0.25 
mg/dL at the time of the final infusion. Creatinine levels were 0.71 ± 0.17 mg/dL at 
baseline and 0.75 ± 0.18 mg/dL at the time of the final infusion. Baseline and final serum 
phosphorous levels were 3.78 ± 0.57 mg/dL and 3.78 ± 0.65 mg/dL, respectively. 
Overall, there were no observable side effects from high dose vitamin D therapy, as seen 
in the blood chemistry lab levels (Table 7). 
Table 7: Blood chemistry to monitor the safety of study therapy. Blood chemistry 
labs were observed to identify incidents of hypercalcemia or hypercalciuria. There was 
no significant impact of high dose therapy on CHEM10 labs from the initial to end of the 
study. 
mg/dL Calcium Creatinine Phosphorous 
50K IU    
  Baseline 9.26 ± 0.45 0.63 ± 0.24 3.82 ± 0.64 
Final (Infusion 12) 9.43 ± 0.42 0.60 ± 0.21 4.06 ± 0.68 
100K IU    
Baseline 9.34 ± 0.33 0.71 ± 0.17 3.78 ± 0.57 
Final (Infusion 8) 9.48 ± 0.25 0.75 ± 0.18 3.78 ± 0.65 
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Spot urine calcium to creatinine ratio was not collected at baseline but was 
measured at every other infusion (even-numbered infusions) to monitor for the 
development of hypercalciuria. The mean spot urine Ca/Cr ratios in both dosing groups 
did not exceed 0.200 from baseline to the end of the study, nor was there a significant 
increase in either serum calcium or creatinine levels. The mean spot urine Ca/Cr was 
0.075 ± 0.061 when first measured at Infusion 2 and 0.098 ± 0.050 at the final (12) 
infusion (t, 1.02; CI, -0.07 – 0.03; p = 0.38) in the 50,000 IU dose group. Similarly, there 
was no significant increase in urine spot Ca/Cr in the 100,000 IU dose group in the 
interval between Infusion 2 (0.100 ± 0.098) and Infusion 8 (0.096 ± 0.079; t, 0.85; CI, -
0.04 – 0.05; p = 0.85). 
Repeat spot urine samples were requested if a patient’s measured Ca/Cr was 
greater than 0.200. A more definitive 24-hour urine Ca/Cr ratio was ordered if both spot 
urine measurements were greater than 0.200. Of the 60 patients who received three or 
more doses of oral vitamin D3 as part of the study, 11(18%) had at least one measured 
urine Ca/Cr ratio > 0.200, and 3 (5%) had an elevated follow-up Ca/Cr. These 3 patients 
then completed 24-hour urine collections. In each of these cases, normal 24-hour urine 
calcium to creatinine ratios were noted (Table 8). Of note, in the 50,000 IU dose group, 
there were no patients who recorded an elevated Ca/Cr ratio at either Infusion 10 or 12. 
Furthermore, there were no incidents of kidney stones or serologic (Blood Urea Nitrogen 





Table 8: Incidence of elevated urine calcium. Spot urine Ca/Cr were measured at every 
other infusion over a year and categorized as either “Normal” (≤ 0.200) or “Elevated” 
(>0.200). Patients who recorded an elevated urine Ca/Cr had a follow-up urine sample 
measure at the following infusion. No patient recorded more than 2 consecutive high 
urine Ca/Cr. 
 Infusion 2 Infusion 4 Infusion 6 Infusion 8 TOTAL 
50,000 IU # of subjects     
Normal    14 (100%) 16 (94%) 17 (94%) 17 (100%) 64 (97%) 
Elevated      0 (0%) 1 (6%) 1 (6%)    0 (0%) 2 (3%) 
Elevated: Follow-up        -- 0 (0%) 0 (0%)      -- 0 (0%) 
100,000 IU # of subjects     
Normal    34 (92%) 34 (87%) 32 (91%) 33 (97%) 133 (90%) 
Elevated     3  (8%)   5 (13%) 3 (9%)     1 (3%) 12 (8%) 
Elevated: Follow-up     0  (0%)       2 (5%)     1 (3%)     0 (0%)    3 (2%) 
 
No adverse events were reported during the study. There were also no enrolled 
subjects who experienced Remicade infusion side effects while on the study. One 
consented patient who had a history of nausea related to vitamin D3 supplementation 
opted to withdraw from the study when they experienced similar symptoms after 
receiving their first study dose. However, no adverse effects were reported by any of the 
remaining enrolled subjects in the study. 
 
Disease Activity 
Baseline disease activity data were assessed by the subject’s most recent aPCDAI 
or PUCAI scores for patients with CD or UC, respectively. 45 patients with CD and 14 
patients with UC had disease activity assessed within 8 weeks of their qualifying serum 
25OHD level and before administration of the first study dose. Disease activity metrics 
were not collected for the one patient with indeterminate colitis as aPCDAI or PUCAI 
were not applicable in their case. Of the 45 patients diagnosed with CD, 32 (71%) of 
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these patients had a reported aPCDAI score at both baseline and at the time of their final 
infusion. A paired t-test analysis revealed a negative trend, but no significant change in 
average aPCDAI scores from the start (3.8 ± 8.0) to the end (1.7 ± 3.7) of the study (t, 
1.39; CI, -0.98 – 5.22; p = 0.17). There was a similar negative relationship noted between 
UC and PUCAI scores in response to vitamin D therapy, but it did not reach statistical 
significance. Of the 14 patients with UC, 9 (64%) had PUCAI scores available at both 
baseline and their final infusion (either at Infusion 8 or Infusion 12). Paired t-test analysis 
of the change in mean PUCAI scores from baseline (7.2 ± 13.0) to study conclusion (6.1 
± 8.2) revealed a negative trend, but no significant decrease (t, 0.27; CI, -8.26 – 10.48; p 
= 0.79) in disease activity scores in response to high dose interval vitamin D 
supplementation. (Table 9). 
Table 9: Effect of high dose therapy on disease activity. aPCDAI score was identified 
in 32 of the 45 CD patients at baseline and final dose. PUCAI score was defined in 9 of 
the 14 UC patients at baseline and at the time of their last dose. Higher scores indicate 
disease severity. Though there was a decrease in scores noted in both groups throughout 
the study, this difference did not reach statistical significance (p < 0.01). 
 aPCDAI PUCAI 
Baseline 3.8 ± 8.0 7.2 ± 13.0 
Final 1.7 ± 3.7 6.1 ± 8.2 
p-value 
(*significant if p < 0.01) 
0.17 0.79 
 
Health Related Quality of Life (IMPACT-III) 
Enrolled subjects and/or their guardians completed a quality of life questionnaire 
(IMPACT-III) at time of consent, which was within eight weeks of a deficient serum 
25OHD level (<30 ng/mL), and then again at the end of the study. Two patients either 
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failed to complete the initial HRQoL survey or return it within eight weeks of the 
qualifying lab date, leaving 58 (97%) patients with paired HRQoL metrics. The average 
IMPACT-III score at baseline was 140.8 ± 18.8 (minimum score of 94.0, a maximum 
score of 169.0, and a median score of 146.5). Of the 60 enrolled patients in the study, 45 
(75%) patients filled out the IMPACT-III survey at their last vitamin D administration 
with an average score of 146.5 ± 16.3 (minimum score of 101.0, maximum score of 
169.0, and a median score of 149.0). Paired IMPACT-III scores were available for 42 
patients. While there was an overall increase (142.4 ± 18.2 to 146.1 ± 16.5) in IMPACT-
III scores, this difference did not reach statistical significance by paired t-test analysis (t, 
2.02; CI, -7.31 – 0.00; p = 2.02). 
Post-hoc analysis demonstrated small improvements in IMPACT-III scores in 
both dosing and disease subgroups (CD and UC), but these increases were not 
statistically significant. 18 subjects in the 50,000 IU dose group completed the IMPACT-
III survey at baseline, and 12 (67%) of these patients completed IMPACT-III surveys at 
their final dose (Infusion 12). Paired t-test analysis of the change in mean IMPACT-III 
scores from baseline (131.9 ± 21.2) to last (139.6 ± 22.1) dosing was not statistically 
different (t, 1.77; CI, -17.21 – 1.87; p = 0.15). A similar trend was noted among the 42 
patients in the 100,000 IU dose group (Figure 6). Of these, 30 (71%) patients completed 
the IMPACT-III survey at both baseline and at the time of their final vitamin D dose 
(Infusion 8). A paired t-test analysis revealed a lack of statistical significance in their 
changes from the initial (146.5 ±  15.4) to final (148.6 ±  13.4) measurements (t, 1.14; CI, 
-5.87 – 1.68; p = 0.27). 
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Figure 6: IMPACT-III scores across the total study population and dosing 
subgroups. 42 of the 60 enrolled patients completed both IMPACT-III forms. 12 of the 
18 subjects in the 50,000 IU dose group and 30 of the 42 patients in the 100,000 IU dose 
group returned both forms. Higher scores reflect improved quality of life. No significant 
increase in scores was observed (p < 0.01). 
 
 
32 (71%) of 45 patients with CD completed both IMPACT-III surveys. Paired t-
test analysis demonstrated no statistically significant increase in IMPACT-III scores 
among CD patients from baseline to final dose administration, with mean scores of 144.6 
± 15.3 and 146.6 ± 15.3, respectively (t, 1.06; CI, -6.12 – 1.93; p = 0.30). 9 of 14 (64%) 
patients with UC completed both IMPACT-III questionnaires. The HRQoL scores of 
these nine patients revealed no significant increase (baseline to final dosage) in IMPACT-
III scores as assessed by paired t-test analysis (Figure 7). Mean IMPACT-III scores 
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the 1 patient with IC had an IMPACT-III score of 122.0 at baseline and an IMPACT-III 
score of 157.0 at their final infusion. 
 
 
Figure 7: IMPACT-III scores across the total study population and disease state. 42 
of the 60 enrolled patients completed both IMPACT-III forms. 32 of the 45 CD patients 
and 9 of the 14 UC patients returned the surveys at baseline and then at final vitamin D3 
administration. Higher scores indicate an increased quality of life. No significant increase 




























This prospective research study investigated the safety and efficacy of high dose 
vitamin D supplementation in a large sample of vitamin D deficient pediatric patients 
with IBD. This therapy was administered in the context of regularly scheduled Remicade 
infusions, and this dosing protocol was designed to optimize convenience and to ensure 
study compliance. The administration of vitamin D3 during scheduled Remicade 
infusions also afforded increased opportunities for careful observations of each subject’s 
clinical symptoms as well as to collect relevant safety measures. 
 
Study Sample Population 
The study was conducted in a population of pediatric patients at BCH with 
deficient levels of vitamin D. Data from previous studies has demonstrated that children 
with IBD are at a higher risk of extraintestinal manifestations when they are diagnosed 
before the age of 20 and thus are more susceptible to long-term clinical symptoms 
(Kelsen et al., 2008). One of the advantages of this study was the ability to conduct it 
within a large population of patients with IBD, followed by a limited number of providers 
in a single facility (Boston Children’s Hospital). Many of these patients were not actively 
taking other vitamin D supplementation, and this made it easier to assess the impact of 





Vitamin D deficient patients with IBD receiving Remicade were administered oral 
doses (50,000 IU or 100,000 IU) of vitamin D3 during their scheduled Remicade 
infusions, either from 4-5 weeks or 6-8 weeks, respectively. Patients enrolled in the study 
had a serum 25OHD level of 22.53 ± 4.65 ng/mL at baseline, and a final serum 25OHD 
level of 29.91 ± 6.60 ng/mL (Figure 3). This reflects an approximate 7 ng/mL increase in 
vitamin D levels from start to finish. Patients receiving 50,000 IU experienced a rise in 
serum 25OHD from a baseline level of 20.28 ± 6.29 ng/mL to a final 25OHD level of 
28.54 ± 7.32 ng/mL. Patients receiving 100,000 IU also experienced a significant 
increase in 25OHD vitamin D levels from baseline (23.42 ± 3.55 ng/mL) to final (8) 
infusion (30.44 ± 6.35 ng/mL; Figure 4). 
A retrospective study in New Zealand demonstrated that a single dose of 100,000 
IU was sufficient to increase serum 25OHD vitamin D levels from baseline for about four 
months (Martin, Rigterink, Adamji, Wall, & Day, 2019; Ilahi et al., 2008). The current 
study intended to assess the impact of repeated, interval, vitamin D supplementation over 
a longer course, rather than a single dose administered at a single point in time. 
Therefore, 25OHD levels were measured every 4-5 weeks for 48-60 weeks for the 50,000 
IU dose group and every 6-8 weeks for 48-64 weeks for patients in the 100,000 IU dose 
group. Our data demonstrated that continuous and repeated interval supplementation is 
likely capable of sustaining sufficient vitamin D levels in the long term. To our 
knowledge, this is the first study to prospectively monitor serum 25OHD levels in 
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response to repeated administrations of high dose oral vitamin D supplementation in 
pediatric patients with IBD. 
Although a significant increase in mean serum 25OHD levels was noted across 
the study population, higher mean serum 25OHD levels were not achieved in all study 
subjects. These patients may have been susceptible to increased vitamin D metabolic 
rates. The increase in metabolism could either occur mechanistically through the inability 
of vitamin D 25-hydroxylase to convert vitamin D3 to 25OHD. Alternately, negative 
feedback from 1,25(OH)2D might trigger the degradation of 25OHD by 25OHD 24-
hydroxylase. However, data collected in this project did not include serial measurements 
of vitamin D3 or 24,25(OH)2D3 levels. Further investigation into vitamin D metabolism 
shifts in vivo in response to vitamin D supplementation is necessary to address this issue 
further. These data may ultimately demonstrate that changes in vitamin D levels may be 
related to the dosing and/or ambient serum level of vitamin D3 supplementation itself. 
This intervention study was designed to assess the safety and efficacy of high 
dose, interval vitamin D therapy in an undertreated population. As such, we chose not to 
include a placebo control group. The enrolled population included about twice as many 
male subjects, and approximately 70% of the study population race was white. This 
profile is similar to the overall demographics of patients treated in the Center for 
Inflammatory Bowel Disease at BCH. The degree of baseline serum 25OHD deficiency 
was not dictated by race, gender, age, or BMI. Therefore, it does not follow that the 
approach to high dose therapy should differ among patients based upon these 
demographic characteristics and do not need to be taken into immediate consideration 
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when determining the potential impact of vitamin D therapy in pediatric patients with 
IBD. 
Significant increases in serum 25OHD levels were noted in both CD and UC 
patients throughout the study. There were three times as many patients with CD (42) than 
with UC (14). Patients with CD had a baseline serum 25OHD level of 22.31 ± 4.73 
ng/mL and a final serum 25OHD level of 29.68 ± 6.35 ng/mL, while patients with UC 
had baseline serum 25OHD levels of 23.02 ± 4.68 ng/mL and final serum 25OHD levels 
of 29.99 ± 7.40 ng/mL (Figure 5). Of note, patients with both CD and UC manifest an 
overall significant increase in serum 25OHD levels from baseline to last dose 
administration. However, there was no significant difference in serum 25OHD levels in 
comparison to each other. This is consistent with data from other studies that has 
demonstrated a lack of remarkable difference between average serum 25OHD levels in 
patients with either CD or UC (Li et al., 2019). The ratio of pediatric patients with CD to 
those with UC in this study is representative of a cross-section of the pediatric IBD 
population in New England. The changes in serum 25OHD levels were not significantly 
different between the two groups throughout the study. The enrolled population did not 
correlate with the 50:50 ratio (25 patients with CD and 25 patients with UC) that were 
initially submitted to the IRB study protocol. Future studies should be designed to adjust 
the number of pediatric patients in each cohort to assess better for the presence of a 





Serum chemistry labs were collected in the context of scheduled clinical care to 
assess for potential side effects associated with high dose vitamin D3 therapy. There were 
no significant changes in serum calcium, creatinine, or phosphorous levels noted in either 
dosing groups throughout the study (Table 7). Active 1,25(OH)2D maintains serum 
calcium and phosphorous levels by binding with VDR in the intestinal epithelium 
(Fukumoto, 2014). Therefore, increased levels of vitamin D have the potential to increase 
serum calcium and phosphorous levels and thereby contribute to enhanced urinary 
excretion of calcium and phosphate. PTH works in tandem with 1,25(OH)2D to modulate 
phosphorous and calcium release from bone and to counter the effects of 1,25(OH)2D 
function in the kidneys by blocking reabsorption and increasing urinary excretion of 
phosphate. Fibroblast growth factor 23 (FGF23) is a more potent regulator of vitamin D 
metabolism through its inhibition of 25OHD 1α-hydroxylase activity in response to 
increased 1,25(OH)2D levels (Fukumoto, 2014). Therefore, increases in 1,25(OH)2D 
levels in response to vitamin D3 supplementation could stimulate increases in circulating 
FGF23 to decrease total calcium and phosphorus levels. Unfortunately, this study was not 
funded to support collection and serial measurement of 1,25(OH)2D levels, PTH, or 
FGF23. Nonetheless, the lack of significant changes in calcium and phosphorous levels 
was sufficient to monitor for the safety of exogenous vitamin D3 therapy. Future studies 
would be useful to gain a better understanding of the relationship between circulating 
PTH and FGF23 levels on vitamin D status. 
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Spot urine Ca/Cr samples were collected to monitor for hypercalciuria and 
increased risk of kidney stones. No significant changes in urine Ca/Cr were measured 
from baseline to final vitamin D3 administration in both dosing groups. 11 patients had at 
least one elevated urine Ca/Cr > 0.200. Of the 3 patients with an elevated follow-up spot 
urine Ca/Cr, all had normal 24-hour urine Ca/Cr ratios (Table 8). While several factors 
may have contributed to the elevated spot urinary calcium to creatinine ratios in these 
patients, these increased levels were likely related to dietary variance. Increased dietary 
calcium absorption can trigger a reflex increase in renal calcium excretion to maintain 
serum calcium homeostasis. While urine spot collections may not provide the most 
definitive data concerning calcium status, the scope of this assay is sufficient to assess for 
potential side effects of vitamin D3 therapy. The aggregate urinary data collected in this 
study demonstrate that the interval, high dose therapy employed in this study does not 
pose a risk for vitamin D deficient pediatric patients with IBD. 
There were no observed adverse effects concerning vitamin D3 administration 
throughout the study. Only one subject elected to remove themselves from the study 
when they experienced nausea after receiving their first dose of vitamin D3. Although 
nausea, along with drowsiness, loss of appetite, and headaches, can indicate early 
symptoms of vitamin D toxicity, this would have been unlikely given the near-immediate 
onset after the initial study dose (Alshahrani & Aljohani, 2013). It is indeed possible that 
the nausea that the patient experienced was due to other unrelated factors, including food 
sensitivity or other IBD-related clinical symptoms. In summation, the data from this 
study demonstrate that high dose vitamin D does not significantly affect serum and urine 
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phosphorous, calcium, and creatinine levels and thus support this dosing protocol as a 
minimal risk intervention (Table 7). 
 
Disease Activity and IBD Symptoms 
A secondary aim of this study was to investigate the impact of vitamin D 
supplementation on both disease activity and quality of life in pediatric patients with 
IBD. Disease activity analysis was assessed as aPCDAI in patients with CD and PUCAI 
in patients with UC. Increased scores indicate worsening disease severity. For patients 
with CD, there was no significant decrease in average aPCDAI scores from baseline to 
final infusion. (Table 9). Data from a previous study demonstrated an association 
between vitamin D supplementation and improvement in aPCDAI scores. However, 
patients in this study received only a single dose of vitamin D3, and patients with UC 
were excluded (Martin et al., 2019). The average aPCDAI and PUCAI scores in this 
study were consistent with patients in clinical remission (<10 points for aPCDAI and 
PUCAI; Kim, Kang, Park, Koh, & Kim, 2019). As such, it is possible that improvements 
in vitamin D status would not affect the disease activity scores of the majority of these 
patients due to the lack of fluctuations in their symptoms. On the other hand, other IBD-
related symptoms, such as bloating, abdominal pain, and diarrhea (not necessarily 
captured in existing PCDAI and PUCAI scoring), may have been impacted upon by 
therapeutic vitamin D dosing (Perler et al., 2019). Lastly, a previous study failed to 
demonstrate a correlation between 25OHD levels and clinical markers of systemic 
inflammation in pediatric patients with IBD (Garg et al., 2019). Therefore, it is also 
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possible that the average ~7 ng/mL increase from baseline to final infusion across the 
study population was not of significant magnitude to influence changes in clinical 
manifestations. For these above reasons, larger-scale studies would be necessary to more 
definitively assess the direct impact of vitamin D status on disease activity in a study 
population of pediatric CD and UC patients. 
Patients completed IMPACT-III surveys at baseline and at the conclusion of the 
study to evaluate the change in their quality of life scores in response to long-term 
vitamin D3 therapy. Across both dose and disease groups, mean IMPACT-III scores 
increased from baseline to final infusion, but this increase did not prove to be statistically 
significant. IMPACT-III scores in the 50,000 IU dose group increased from 131.9 ± 21.2 
at baseline to 139.6 ± 22.1 at final dose administration. The increase in IMPACT-III 
scores was more modest (146.5 ± 15.4 vs. 148.6 ± 13.4) in the 100,000 IU dosing group 
(Figure 6). The IMPACT-III scores in patients with CD rose from 144.6 ± 15.3 to 146.6 ± 
15.3. Patients with UC experienced a more generous (137.0 ± 8.8 vs. 142.9 ± 7.2) 
increase (Figure 7). As previously mentioned, the opportunity for vitamin D3 therapy to 
affect IMPACT-III scoring may have been muted, as many of these patients remained in 
remission throughout the study (Abdovic et al., 2013). Of note, 30% of subjects in the 
study failed to complete paired IMPACT-III surveys at the time of enrollment and study 
closure and were therefore excluded from this analysis. As such, future studies may 
identify more conclusive data demonstrating a positive correlation between vitamin D 




Conclusions and Future Studies 
Our data demonstrate that high dose vitamin D3 supplementation administered 
coincident with scheduled Remicade infusions is a safe and effective method for 
increasing serum 25OHD levels in pediatric patients with IBD who are deemed vitamin 
D deficient. Steady-state serum 25OHD levels (~30 ng/mL) were achieved after three 
doses in both dosing groups, and in patients with both CD and UC, throughout the study. 
Mean serum 25OHD levels increased an average of 7 ng/mL from baseline to final dose. 
However, approximately 50% of patients with CD and UC remained vitamin D 
insufficient (serum 25OHD <30 ng/mL) at the conclusion of the study. Higher vitamin D 
supplementation may be necessary to achieve and maintain adequate vitamin D levels. 
Data from previous studies has demonstrated that pediatric patients with IBD do not 
consistently achieve vitamin D sufficiency in response to standard dosing (2,000 IU 
daily). However, many patients respond more to a single higher dose (100,000 IU) oral 
supplement without experiencing signs or symptoms of toxicity (Pappa et al., 2014; 
Martin et al., 2019). These data demonstrate the safety and efficacy of high dose vitamin 
D3 supplementation in pediatric patients with IBD. Further studies should address the 
long-term safety profile of high dose supplementation, as well as “treating to target” – the 
recognition that achieving higher target 25OHD levels in some patients may require 
higher doses of vitamin D3 supplementation. 
Vitamin D therapy was correlated with decreased disease activity and increased 
quality of life. However, neither of these findings proved to be statistically significant. It 
is possible that the serum 25OHD levels were not high enough to impact meaningfully on 
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either disease activity and/or quality of life. It is also possible that other variables, such as 
GI-related systemic symptoms or in-patient hospitalizations throughout the study, played 
more of a determining factor in determining disease activity or quality of life. More 
extensive studies should be better enabled to discern whether maintaining therapeutic or 
supra-therapeutic vitamin D3 levels can more significantly impact a patient’s clinical 
symptoms and/or quality of life. 
Vitamin D status can serve as a predictive marker for IBD response to anti-TNFa 
medications, such as Remicade, both before and after the beginning of therapy. 
Retrospective studies have suggested that patients with IBD and vitamin D sufficiency 
have an increased likelihood of experiencing remission when treated with anti-TNFa 
medication (Winter et al., 2017). Assessing the relationship between vitamin D levels and 
clinical response to Remicade therapy was not the primary aim of this study. 
Nonetheless, there was no occurrence of adverse events for patients receiving both 
Remicade and vitamin D3 supplementation. Future prospective studies should further 
investigate whether there is a mechanistic synergy conferred by vitamin D and anti-
TNFa coadministration in pediatric patients with IBD. 
The study protocol levered scheduled Remicade infusions as an opportunity to 
ensure compliance and complete safety monitoring. Therefore, the protocol excluded IBD 
patients in the BCH population who were not treated with this agent. Remicade is a 
conventional intravenous therapy. However, there are now available several other 
medications, including Vedolizumab, that have also proven to be a safe and effective 
parenteral option to treat pediatric patients with IBD (Schneider et al., 2018). 
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Vedolizumab is an α4β7-integrin antagonist that decreases inflammation in the intestines 
and is also administered through regularly scheduled infusions at the hospital. An 
updated protocol currently underway will include pediatric patients with IBD who are 
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